ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0171

Interferon Response Gene Expression Differs in Whole Blood, Peripheral Blood Mononuclear Cells, Monocytes, T Cells, B Cells, and NK Cells in Patients with the Autoinflammatory Interferonopathies, CANDLE and SAVI

Jacob Mitchell1, Sara Alehashemi2, Bernadette Marrero3, Yan Huang4, Sofia Torreggiani1, Lena Bichell1, Gina Montealegre Sanchez5, Raphaela Goldbach-Mansky6 and Adriana de Jesus7, 1Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Bethesda, MD, 2Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Clarksville, MD, 3Computational Systems Biology Section/NIAID/NIH, Bethesda, MD, 4NIH, Bethesda, 5NIAID/NIH, Rockville, MD, 6Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Potomac, MD, 7Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Silver Spring, MD

Meeting: ACR Convergence 2020

Keywords: Autoinflammatory diseases, Biomarkers, interferon, Pediatric rheumatology

  • Tweet
  • Email
  • Print
Session Information

Date: Friday, November 6, 2020

Title: Pediatric Rheumatology – Basic Science Poster

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The disease progression of patients (pts.) with type-I interferon (IFN)-mediated diseases undergoing treatment with JAK1 and JAK2 inhibitors is monitored in part by measuring the transcription of a 28 IFN response gene (IRG) signature in whole blood with Nanostring technology to calculate a 28-gene IFN score. We sought to determine the differences in 28-gene IFN scores and in the patterns of IRG signatures among peripheral blood mononuclear cells (PBMCs), monocytes, CD4 and CD8 T cells, B cells, NK cells, and neutrophils in the type-I IFN-mediated diseases CANDLE (chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures) and SAVI (STING-associated vasculopathy with onset in infancy).

Methods: All patients (pts.) were enrolled into an IRB-approved natural history protocol (NCT02974595). RNA was extracted from pts. and healthy control whole blood, PBMCs, monocytes, CD4 and CD8 T cells, B cells, NK cells, and neutrophils. Transcript counts for 28 IRGs and 4 additional genes were measured with a NanoString instrument and compared to expression in the same cells or tissues in a cohort of healthy controls (HCs).

Results: Both CANDLE (p=0.065) and SAVI pts. (p=0.004) had greater 28-gene standardized IFN scores in whole blood and PBMCs compared to HCs. Significantly higher IFN scores were seen in SAVI PBMCs as compared to SAVI whole blood (p=0.035) while CANDLE PBMC IFN scores were not significantly different compared to CANDLE whole blood. SAVI PBMCs expressed more IFNA2 and IFNB1 than PBMCs from CANDLE pts. (p=0.0023; p=0.0012) or HCs (p=0.0097; p=0.0004). One family of SAVI pts. with a novel STING missense variant was found to have elevated IFN scores in their PBMCs while their whole blood IFN scores were not elevated. In cell subsets isolated from PBMCs, CANDLE and SAVI pts. had elevated IFN scores in monocytes and T cells, but the IFN scores in B cells and NK cells were not significantly different from HCs. SAVI pts. had significantly high IFN scores than CANDLE patients in the monocyte (p=0.02) and CD4 T cell (p=0.002) subsets. Within the 28 IRGs of the IFN score, SAVI and CANDLE monocytes had the highest relative expression of IFIT3 and LY6E, respectively. Preliminary studies in neutrophils have also shown that SAVI neutrophils have a greater induction of IRG transcription compared to CANDLE pts.

Conclusion: High expression of type-1 IFNs and IRGs in the PBMCs of SAVI pts. further demonstrate the role of these cells in the amplification of constitutive IFN signaling in this disease. Monocytes make a substantial contribution to the elevated IRG signature in peripheral blood found in both diseases and to a greater extent in SAVI. In addition, pts. with a SAVI phenotype and genotype but a negative IRG signature in whole blood may present an IRG transcription signature when investigating the PBMC fraction.

Funding for this study was provided in part by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health. All patients were enrolled into an IRB-approved natural history protocol.


Disclosure: J. Mitchell, None; S. Alehashemi, None; B. Marrero, None; Y. Huang, None; S. Torreggiani, None; L. Bichell, None; G. Montealegre Sanchez, None; R. Goldbach-Mansky, None; A. de Jesus, None.

To cite this abstract in AMA style:

Mitchell J, Alehashemi S, Marrero B, Huang Y, Torreggiani S, Bichell L, Montealegre Sanchez G, Goldbach-Mansky R, de Jesus A. Interferon Response Gene Expression Differs in Whole Blood, Peripheral Blood Mononuclear Cells, Monocytes, T Cells, B Cells, and NK Cells in Patients with the Autoinflammatory Interferonopathies, CANDLE and SAVI [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/interferon-response-gene-expression-differs-in-whole-blood-peripheral-blood-mononuclear-cells-monocytes-t-cells-b-cells-and-nk-cells-in-patients-with-the-autoinflammatory-interferonopathies-cand/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/interferon-response-gene-expression-differs-in-whole-blood-peripheral-blood-mononuclear-cells-monocytes-t-cells-b-cells-and-nk-cells-in-patients-with-the-autoinflammatory-interferonopathies-cand/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology